A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

NCT06825858 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-Related Macular Degeneration

Interventions

DRUG: KH658

Sponsor

Chengdu Origen Biotechnology Co., Ltd.